5-amino-1MQ: what the research shows
- By Reed Calder
- Last reviewed Nov 11, 2026
- 18 studies and official documents checked
In short
5-amino-1MQ is a small lab-made molecule, not a peptide. It blocks an enzyme called NNMT, which shows up about twice as high in the fat tissue of people with type 2 diabetes. In obese mice, injections limited weight and fat gain without changing how much they ate. By mouth it was poorly absorbed in mice (3.5%) and better in rats (38%). We found no study of it in people and no registered trial. It isn’t FDA-approved.
EvidenceCellAnimalHuman
5-amino-1MQ is sold online as capsules and vials for fat loss and “metabolism.” It is often listed with peptides, but it isn’t one. This page covers what it is, what the mouse and rat studies found, what we know about taking it by mouth, the safety signals, and where it stands legally.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| 5-amino-1MQ, 5-amino-1-methylquinolinium, 5A1MQ, 5-AMQ, NNMTi | A small molecule with a charged ring structure, formula C10H11N2 and a mass of 159 (PubChem). Papers use several short names for the same compound | No published study found |
| 5-amino-1-methylquinolinium iodide | The salt form used in lab work, with a mass of 286 (PubChem) | No published study found |
| “5-amino peptide,” “5-amino-1MQ peptide” | Sales labels. The compound is not a chain of amino acids, so it isn’t a peptide | No published study found |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. Two CAS numbers are on file: one for the charged ion and one for its iodide salt.
What 5-amino-1MQ is
NNMT (nicotinamide N-methyltransferase) is an enzyme that uses up nicotinamide, a form of vitamin B3. In mice, turning NNMT down in fat and liver protected them from diet-induced obesity (Kraus et al., 2014). In people, fat tissue from those with type 2 diabetes had about twice the NNMT gene activity of fat tissue from those without it, and the level fell after exercise or weight-loss surgery (Kannt et al., 2015).
5-amino-1MQ is a small, charged molecule built to block NNMT and to get into cells. In lab tests it didn’t block related enzymes, and in cultured fat cells it raised NAD+ and SAM, two molecules cells use for energy and methylation, and slowed fat making (Neelakantan et al., 2018). A target that shows up in human tissue is a reason to test a drug in people. It isn’t a result in people.
What has been studied
In people
- No published study of 5-amino-1MQ in people. Every paper we found that tested it used cells, mice or rats. ClinicalTrials.gov has no study for it (searched November 11, 2026).
- What exists in people is about the enzyme, not the compound. Higher NNMT in the fat of people with type 2 diabetes (Kannt et al., 2015) tells researchers where to look. It doesn’t show what a drug does.
In animals and cells
- Obese mice, 11 days. With injections under the skin three times a day (20 mg/kg each, about 34 mg/kg a day of the parent compound), treated mice lost about 5% of their weight (2.0 g) while untreated mice gained 0.6 g. A fat pad weighed in these mice was about 35% lighter, fat cells were more than 30% smaller and total cholesterol was lower. Food intake didn’t change, and the authors saw no obvious side effects. There were 9 mice in each group (Neelakantan et al., 2018).
- Obese mice, about 4 weeks. With one injection a day, the lower dose (10 mg/kg) did nothing to weight gain (5.2 g vs 5.4 g in untreated mice). The higher dose (32 mg/kg) limited gain to 0.9 g and fat gain to 1.3 g, against 4.7 g in untreated mice. Lean mass didn’t differ. Insulin rose less, and livers were lighter (1.4 g vs 2.1 g) with less fat. There were 8 mice per group (Babula et al., 2024).
- Obese mice moved to a lean diet. Over 7 weeks, mice given the compound (4 mg/mL at 10 microliters per gram of body weight, or 40 mg/kg a dose) lost weight and fat faster than mice on the diet change alone, and their body composition and liver fat matched lean control mice by the end. Food intake didn’t differ (Sampson et al., 2021).
- Old mice. In 24-month-old mice with an injured leg muscle, twice-daily injections of 5 or 10 mg/kg made muscle fibers nearly twice as large and raised peak muscle torque about 70% (Neelakantan et al., 2019). In 22-month-old mice given 10 mg/kg, grip strength was about 40% higher than in untreated mice that didn’t exercise, and about 60% higher when they also ran (Dimet-Wiley et al., 2024).
- Cancer models. It slowed tumor growth and boosted an immunotherapy drug in bladder cancer mouse models (Yang et al., 2024) and lowered the survival of bone and skin cancer cells in dishes (Pompei et al., 2025). These are early lab results, and they show NNMT matters outside fat.
- Other inhibitors. A different NNMT-blocking molecule also lowered body weight and improved blood sugar handling in obese mice (Kannt et al., 2018). That supports the target, not 5-amino-1MQ itself.
- Who ran these studies. The obesity and muscle results come from one research group. Three of the papers (2021, 2024 and 2024) say an author founded or works for Ridgeline Therapeutics, a company developing NNMT blockers (Babula et al., 2024; Sampson et al., 2021; Dimet-Wiley et al., 2024). The 2018 and 2019 papers declare no conflicts. We found no obesity or muscle result for 5-amino-1MQ from a group outside this one.
EvidenceCellAnimalHuman
Capsules or injections?
Most products are sold as capsules. The studies that showed weight and fat effects gave injections under the skin. Two studies measured how much reaches the blood when it is swallowed:
| Study | Animal | Route | What reached the blood |
|---|---|---|---|
| Babula 2024 | Mice | By mouth | About 3.5% of a 30 mg/kg dose. The peak blood level was far below the level that blocks the enzyme in a dish (14.5 vs 78 ng/mL) |
| Babula 2024 | Mice | Injection under the skin | A peak about 500 times higher after a 25 mg/kg dose (7,010 ng/mL). It stayed above the enzyme-blocking level for about 2 to 4 hours |
| Awosemo 2021 | Rats | By mouth | About 38% of the dose, and a peak of 2,252 ng/mL |
Mice and rats differ by about ten times, and nobody has measured it in people. So we can’t say whether a capsule delivers anything useful. (Babula et al., 2024; Awosemo et al., 2021)
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| It’s a peptide | Contradicted | No. It is a small molecule with no chain of amino acids (PubChem) |
| Burns fat without cutting appetite | Untested | In obese mice, food intake didn’t change in three studies, and weight and fat fell or rose less (Neelakantan et al., 2018; Babula et al., 2024). The lower dose in one study did nothing. No study in people |
| Keeps or builds muscle | Untested | Lean mass didn’t differ in the 4-week obese-mouse study (Babula et al., 2024). In very old mice with injured muscle, recovery and grip strength improved (Neelakantan et al., 2019; Dimet-Wiley et al., 2024). No study in people |
| Works as a capsule | Untested | Mouse blood levels after swallowing were far below the enzyme-blocking level; rat levels were higher (Babula et al., 2024; Awosemo et al., 2021). Nobody has measured it in people |
| Raises NAD+ | Untested | In cultured fat cells, yes (Neelakantan et al., 2018). We found no measurement in people. For the molecule itself, see our NAD+ card |
| Has no side effects | Untested | The mouse studies saw none that were obvious, but they were small and short (Sampson et al., 2021). One screen found it blocks another enzyme, MAO-A, by 67% at the concentration tested (Babula et al., 2024). No safety study in people |
| Reverses aging | Untested | Only in old mice, for muscle recovery and grip strength (Neelakantan et al., 2019; Dimet-Wiley et al., 2024). No study in people |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies used
| Study | Animal | How given | Length |
|---|---|---|---|
| Neelakantan 2018 | Obese mice | Injection under the skin, 3 times a day, 20 mg/kg each | 11 days |
| Babula 2024 | Obese mice | Injection under the skin, once a day, 10 or 32 mg/kg | About 4 weeks |
| Sampson 2021 | Obese mice on a lean diet | Injection, 40 mg/kg a dose | 7 weeks |
| Neelakantan 2019 | Mice aged 24 months, injured muscle | Injection under the skin, twice a day, 5 or 10 mg/kg | 1 to 3 weeks after the injury |
| Dimet-Wiley 2024 | Mice aged 22 months | Injection, 10 mg/kg | About 2 months |
| Awosemo 2021 | Rats | One dose, by vein or by mouth | Blood samples over hours |
These are the studies’ methods, not a dose for anyone to use. Mouse doses don’t convert to people, and nobody has tested it in people.
Side effects and safety
- There are no human safety data for 5-amino-1MQ. What follows comes from animals.
- No obvious harm in short mouse studies. The authors reported none after 11 days and after 7 weeks, and blood chemistry that didn’t differ between groups in the 7-week study (Neelakantan et al., 2018; Sampson et al., 2021). The studies were small, with 6 to 9 mice per group, and weren’t built to find slow or rare harm.
- One off-target hit. In a screen of receptors, enzymes and transporters at one test concentration, the only strong effect was a 67% block of the enzyme MAO-A. The authors list improving this as ongoing work (Babula et al., 2024). Nobody has tested what it would mean in people.
- NNMT works outside fat. Researchers also study it in aging muscle and in tumor-supporting cells (Neelakantan et al., 2019; Yang et al., 2024). What blocking it for months does in healthy people is unstudied.
- Product quality. Products sold under this name haven’t been through FDA review, and we found no independent test of them that we could verify.
- Unstudied. Long-term use, use with other medicines, use in pregnancy and use in children.
Side effects people report from online products aren’t covered here; they come from users, not studies.
Legal and approval status
- Not FDA-approved. We found no approved drug that contains it (Drugs@FDA; searched November 11, 2026). The FDA’s substance registry has records for the compound and its salts (FDA GSRS), but a registry entry isn’t an approval.
- No registered trial. ClinicalTrials.gov lists no study of it (ClinicalTrials.gov).
- Not on the FDA’s safety-risk page, which covers other compounding substances (FDA, 2026). That is not approval.
- Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
- Sport. The World Anti-Doping Agency’s 2026 list doesn’t name it, but its S0 class prohibits any substance with no government approval for human therapeutic use (WADA, 2026).
- “Research use only” products aren’t approved for use in people.
What to look for if you research it
We don’t name or link sellers. These checks come from the registries:
- The right name and number. The ion is CAS 685079-15-6 and the iodide salt is CAS 42464-96-0 (FDA GSRS; FDA GSRS).
- The right mass. About 159 for the ion and 286 for the iodide salt (PubChem; PubChem). A report that names a method, such as mass spectrometry, tells you more than a purity number alone.
- The amount per capsule or vial, written on the report, not just a percentage.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
What’s still unknown
- Whether it does anything for weight, fat or muscle in people.
- How much a person absorbs from a capsule or an injection.
- Whether any amount is safe, and what happens over months or years.
- Whether outside labs get the same mouse results.
- What is really in the capsules and vials sold online.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention 5-amino-1MQ. We recheck every month. Last checked Nov 11, 2026.
We found no retracted, withdrawn or flagged studies that mention 5-amino-1MQ.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Kraus et al., 2014 | Nature | No retraction or concern |
| Kannt et al., 2015 | Diabetologia | No retraction or concern |
| Neelakantan et al., 2018 | Biochem Pharmacol | No retraction or concern |
| Kannt et al., 2018 | Sci Rep | No retraction or concern |
| Neelakantan et al., 2019 | Biochem Pharmacol | No retraction or concern |
| Sampson et al., 2021 | Sci Rep | No retraction or concern |
| Awosemo et al., 2021 | J Pharm Biomed Anal | No retraction or concern |
| Dimet-Wiley et al., 2024 | Sci Rep | No retraction or concern |
| Yang et al., 2024 | J Immunother Cancer | No retraction or concern |
| Babula et al., 2024 | Diabetes Obes Metab | No retraction or concern |
| Pompei et al., 2025 | Biomolecules | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is 5-amino-1MQ?
A small lab-made molecule that blocks the enzyme NNMT (Neelakantan et al., 2018). It isn’t approved for any use, and we found no study of it in people.
Is 5-amino-1MQ a peptide?
No. A peptide is a chain of amino acids. 5-amino-1MQ is a single small molecule with a mass of 159 (PubChem). The “amino” in its name is a chemical group, not amino acids.
What does 5-amino-1MQ do?
It blocks NNMT. In cultured fat cells that raised NAD+ and SAM and slowed fat making, and in obese mice it limited weight and fat gain (Neelakantan et al., 2018). Nobody has tested it in people.
Does 5-amino-1MQ cause fat loss?
In obese mice, yes: about 5% of body weight over 11 days, and less fat gain over 4 weeks at the higher dose (Neelakantan et al., 2018; Babula et al., 2024). The lower dose in the longer study did nothing. No study in people has measured fat loss.
How long does it take to see results?
We found no human data. In the 11-day mouse study, the weight gap first reached significance on day 6 (Neelakantan et al., 2018). Mouse timing doesn’t convert to people.
Is 5-amino-1MQ the same as NAD+?
No. NAD+ is a molecule cells use for energy. 5-amino-1MQ blocks an enzyme that uses up nicotinamide, and in cultured fat cells it raised NAD+ (Neelakantan et al., 2018). Our NAD+ card covers the molecule itself.
Does it work as a capsule?
Unknown in people. In mice, about 3.5% of an oral dose reached the blood, and in rats about 38% (Babula et al., 2024; Awosemo et al., 2021). The mouse studies that showed weight effects used injections.
Does it preserve muscle?
Lean mass didn’t differ in the 4-week obese-mouse study (Babula et al., 2024). In very old mice with injured muscle, recovery improved (Neelakantan et al., 2019). Nothing in people.
What are the side effects of 5-amino-1MQ?
No human studies exist. The mouse studies reported no obvious side effects (Neelakantan et al., 2018), but they were small and short, and one screen found it blocks the enzyme MAO-A by 67% at the concentration tested (Babula et al., 2024).
How long can you take it?
No human safety study exists. The longest mouse studies ran about 2 months (Dimet-Wiley et al., 2024).
What is the 5-amino-1MQ dosage?
No dose comes from a study in people. Mouse studies gave injections under the skin: 20 mg/kg three times a day for 11 days (Neelakantan et al., 2018), 10 or 32 mg/kg once a day for about 4 weeks (Babula et al., 2024) and 5 or 10 mg/kg twice a day in old mice (Neelakantan et al., 2019). In absorption tests, mice got 30 mg/kg by mouth or 25 mg/kg under the skin (Babula et al., 2024). Dose charts online aren’t evidence.
Is 5-amino-1MQ legal?
It isn’t FDA-approved for any use, and it isn’t in the October 2026 HHS policy (Reuters, 2026). Our guide to what to look for covers the routes people use.
Where can I buy 5-amino-1MQ?
Sellers offer it, but it has no approved use and we found no independent test of the products that we could verify. We don’t link sellers; see what to look for.
Sources
- Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-52. PubMed 29155147
- Babula JJ, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024;26:5272-82. PubMed 39161060
- Sampson CM, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Sci Rep. 2021;11:5637. PubMed 33707534
- Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. 2019;163:481-92. PubMed 30753815
- Dimet-Wiley AL, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep. 2024;14:15554. PubMed 38969654
- Awosemo O, et al. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. 2021;204:114255. PubMed 34304009
- Kannt A, et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia. 2015;58:799-808. PubMed 25596852
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508:258-62. PubMed 24717514
- Kannt A, et al. A small molecule inhibitor of nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep. 2018;8:3660. PubMed 29483571
- Yang M, et al. NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer. J Immunother Cancer. 2024;12. PubMed 39067875
- Pompei V, et al. Small molecule inhibitors of nicotinamide N-methyltransferase enzyme for the treatment of osteosarcoma and Merkel cell carcinoma: potential for the development of a targeted therapeutic strategy. Biomolecules. 2025;15. PubMed 41301471
- National Center for Biotechnology Information. PubChem compound records CID 950107 (5-amino-1-methylquinolinium) and CID 66522933 (iodide). PubChem
- ClinicalTrials.gov search for 5-amino-1MQ and 5-amino-1-methylquinolinium, November 11, 2026: no registered studies. Search
- U.S. Food and Drug Administration. Drugs@FDA database; no product with 5-amino-1-methylquinolinium as an active ingredient, searched November 11, 2026. Drugs@FDA
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
- World Anti-Doping Agency. 2026 Prohibited List (S0, non-approved substances). WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- U.S. Food and Drug Administration. Global Substance Registration System: 5-Amino-1-methylquinolinium (UNII PMX593N4N3). GSRS
- U.S. Food and Drug Administration. Global Substance Registration System: 5-Amino-1-methylquinolinium iodide (UNII K9G33W2TTZ). GSRS
Last reviewed Nov 11, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.